drug like News
-
Leucine-Enkephalin as a Novel Analgesic: Efficacy and Safety in Pre-Clinical Models
Endogenous peptides with analgesic potential include endorphins via the mu receptor, dynorphins via the kappa receptor and enkephalins via the delta receptor. Kappa and delta opioid agonists have been shown to provide analgesic benefit while sparing toxic mu agonist toxicity1 . Preclinical data supports analgesia from enkephalin without significant opioid tolerance, or drug liking. Unfortunately, ...
-
Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference
Positive results confirm findings from prior studies evaluating the abuse potential of cebranopadol, further highlighting its potential as a safe and potent alternative to traditional opioids Registrational phase 3 clinical trials of cebranopadol in moderate to severe acute pain are on track to initiate in Q4 2023 – Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage ...
-
Insilico Medicine Initiates First-in-Human Study of ISM001-055, a Novel Drug Discovered Using Insilico`s Proprietary End-to-end Artificial Intelligence Platform
Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the first healthy volunteer has been dosed in a first-in-human microdose trial of ISM001-055. ISM001-055 is a potentially first-in-class small molecule inhibitor of a novel biological target discovered by Pharma.AI, Insilico Medicine's end-to-end AI-powered drug discovery platform. ...
-
Creative Biostructure Offers MagHelix™ Library Design and Preparation Service for Research Use
With decade of service experience in the field of structural biology and advanced computational drug design platform, Creative Biostructure now provides MagHelix™ Library Design and Preparation service that helps step forward its customers’ critical hit screening with reduced timing and escalated “hit rate”. The process of identifying molecules that may become medications ...
-
Oligomerix Awarded $3.35M from NIH to Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced an award of $3.35 million from the National Institute on Aging of the National Institutes of Health to support clinical development of its lead program OLX-07010, an oral tau self-association small molecule ...
-
Optibrium and Lhasa Limited advance predictive modelling for drug-metabolising enzymes
Optibrium and Lhasa Limited publish joint peer-reviewed research in the Journal of Medicinal Chemistry, expanding predictive modelling beyond human Cytochrome P450. Study demonstrates novel predictive models for drug metabolism to improve drug design and Optibrium and Lhasa Limited, two of the leading developers of software and artificial intelligence (AI) solutions for drug discovery and ...
-
Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers
Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-designed molecules for the treatment of methylthioadenosine phosphorylase (MTAP)-deleted cancers. The PCC is part of Insilico's growing ...
-
CD ComputaBio Releases AutoDock Vina Software to Accelerate Molecular Docking Projects
CD ComputaBio, a reliable computational biology service provider in New York, is committed to assisting research and trials, as well as providing access to the latest software, technologies, and expertise with competitive prices and fast turnarounds for researchers. The company has recently announced the introduction of its Autodock Vina software, designed to predict the mechanism of small ...
-
Confo Therapeutics Awarded EUR 1M VLAIO Grant For Pre-Clinical Development Of CFTX-1554, An AT2R Modulator For The Treatment Of Neuropathic Pain
Confo Therapeutics Awarded EUR 1M VLAIO Grant for Pre-Clinical Development of CFTX-1554, an AT2R Modulator for the Treatment of Neuropathic Pain Ghent, Belgium – March 30, 2021 – Confo Therapeutics announced today that it has been awarded a EUR 1 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will support the pre-clinical development of CFTX-1554, ...
-
Suono Bio, Inc. Announces Oversubscribed Series A Funding Round Led by Axil Capital and Mizuho Securities Principal Investment
Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced it has raised an $8.5 million Series A financing led by Axil Capital and Mizuho Securities Principal Investment, with participation by Taiwania Capital and other investors. Suono Bio will utilize the funds to advance its lead programs in inflammatory bowel disease as well as expansion of its ...
By Suono Bio
-
CD Formulation Provides Moisture Content Determination for Drug Formulation and Analysis
Moisture testing is viewed as one of the most fundamental quality parameters to ensure drug stability. Earlier this month, CD Formulation announces the release of moisture content determination service of active pharmaceutical ingredients (APIs) and inactive ingredients for researchers who are engaged with drug development and formulation. Moisture determination is an important aspect of many ...
-
Atriva Therapeutics announces efficacy of its lead compound zapnometinib against Omicron
Strong preclinical evidence of universal efficacy of zapnometinib against coronavirus variants of concernProf. Planz will continue to serve Atriva as Chairman of the Scientific Advisory Board The findings underscore the importance of new therapeutic approaches such as zapnometinib, which can maintain potent efficacy against all coronavirus strains, including Omicron Atriva Therapeutics ...
-
CD ComputaBio Announces PD-L1 Targeting Service for Anticancer Drug Research
CD ComputaBio, a reliable computational biology service provider located in New York, is always hammering away at research and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. The company recently announced the launch of PD-L1 targeting service for cancer research. Over the past decade, ...
-
CD Formulation Launches API Chemical Modification Services to Address Drug Solubility, Bioavailability, and Dissolution Rate Issues
Having abundant expertise in drug formulation and pharmaceutical preparation, the New York-based CRO company CD Formulation recently announces that it is now capable of conducting a wide range of API chemical modification services, including pH modification drug molecular service, drug salt formation service, drug pegylation service, and different groups of precursor drug design service, to help ...
-
Big Data Meets Big Biology in San Diego: Some Takeaways
At the end of the 19th century, the German scientist Paul Ehrlich began to realize that certain chemicals could have highly specific effects on certain diseases. He began to write about the possibility that a drug could act like a magische kugel—magic bullet—that killed only the organism causing disease, and nothing else. Today, scientists are amassing a new arsenal of ...
-
Bristol Myers Squibb exercises option to develop Exscientia’s AI-designed, immune-modulating drug candidate
First candidate in multi-target collaboration to reach in-license milestone BMS to take responsibility for clinical and commercial development Exscientia receives $20 million option exercise fee with additional development milestones as well as tiered royalties on product sales OXFORD, U.K. – August 18, 2021 – Exscientia, a clinical-stage, artificial intelligence (AI)-driven ...
By Exscientia
-
Cancer Targeted Technology Receives an SBIR Grant and Announces Expansion of Its Pipeline
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology company focusing on small molecules that bind to pivotal enzyme cancer targets, announced that it received a Small Business Innovation Research (SBIR) grant to develop CTT1700, a unique prodrug targeted at men with prostate cancer that express Prostate Specific Membrane Antigen (PSMA). PSMA is over-expressed on ...
-
[IB Tomato] (VC Portfolio) Villix, Containing the Identity of Reverse Idea and Novelty
[IB Tomato Reporter Lim Seong-ji] “The new drug development industry is a specialized area that is difficult for general investors and shareholders to understand, and it is difficult to deliver accurate information even when publicly available. The bad examples of some companies that have been inflated even with content are hindering the development of the Korean pharmaceutical and bio ...
-
Poietis announces formation of Scientific Advisory Board and appoints two first prominent Regenerative Medicine experts
Poietis, 4D Bioprinting company, announces formation of Scientific Advisory Board (SAB) and appointment of two first prominent Scientists in Regenerative Medicine. The SAB will serve as a key strategic resource to Poietis as the company expands capabilities of Next- Generation Bioprinting (NGB) platform to therapeutic applications and develops first implantable tissues such as a ...
By Poietis
-
VeriSIM Life Enters into Collaboration Agreement with Mayo Clinic to Jointly Advance Drug Discovery and Development Programs
VeriSIM Life (VeriSIM) www.verisimlife.com, a leading artificial intelligence (AI)-enabled company providing services to de-risk R&D decision making for breakthrough drug development, today announced that it has entered into a collaboration with Mayo Clinic to improve the preclinical translation of promising drug candidates. “We are excited to expand our common mission and work with ...
By VeriSIM Life
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you